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Sumnuay To provide an accurate evaluation of the association of human papillomavirus (HPV) with lung
cancer. 36 cases of lung cancer were analysed for HPV DNAs by polymerase chain reaction (PCR) with
dot-blot and Southern blot analyses, and for the transcripts from the E6-E7 transforming region by in situ
hybridisation (ISH). HPV-18 DNA was detected in three (8%) of 36 specimens; histologically. in one (10%) of
10 squamous cell carcinomas and two (9%) of 22 adenocarcinomas. Neither HPV-16 nor -33 DNA was
detected in any cases examined. Expression of E6-E7 mRNA was confirmed in the cases which contained
HPV-18 DNA. HPV-18 may play an important role in the development and progression of cancer in some
cases of both squamous cell carcinoma and adenocarcinoma of the lung.
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Human papillomaviruses (HPVs) are a heterogeneous group
ofdouble-stranded, non-enveloped DNA viruses with over 60
genotypes (for review, see de Villiers, 1989). They cause
benign epithelial proliferations, but some types of HPV have
been implicated in the pathogenesis of carcinomas for many
sites, including the anogenital area, oropharynx and upper
respiratory tract (Shindoh et al., 1992; Stoler et al., 1992;
Anwar et al., 1993). In particular, more than 90% of cervical
carcinomas contain HPV DNAs that usually correspond to
HPV-16 and HPV-18, so-called 'high-risk HPVs', and, less
frequently, HPV-31. -33 and -35 (for review, see zur Hauzen,
1991).
High-risk HPV DNAs are frequently integrated into cel-
lular DNA in these cancers. and the long-control region and
the E6 and E7 regions of the HPV genome are preferentially
conserved, although other regions of the genome are often
deleted (Schwarz et al.. 1985; Takebe et al., 1987). The E6
and E7 regions of high-risk HPVs can immortalise primary
human cervical, epidermal, mammary and even bronchial
epithelial cells (Woodworth et al., 1988; Hawley et al., 1989;
Band et al.. 1990; Willey et al., 1991). The E6 and E7
proteins of high-risk HPVs bind to the proteins encoded by
the host tumour-suppressor genes. the p53 and retinoblas-
toma susceptibility (RB) genes respectively, to disrupt their
normal function for controlling the cell cycle (Munger et al..
1989; Scheffner et al., 1990; Werness et al., 1990).
Recent studies revealed that the p53 gene is mutated in
73% of small-cell lung cancers (SCLCs) and 45% of non-
small cell lung cancers (NSCLCs) (Chiba et al., 1990;
Takahashi et al., 1991) and that the RB gene is inactivated in
60-100% of SCLC cell lines and 32% of primary NSCLCs
(Harbour et al., 1988; Yokota et al., 1988; Reissmann et al.,
1993). Because alterations of the p53 and RB genes are
involved in many lung cancers, pulmonary infection with
high-risk HPV might play an important role in the develop-
ment and progression of lung cancer through the inactivation
of the p53 and RB genes.
In lung cancer, HPV DNAs have been recently identified
by in situ DNA hybridisation and Southern blot hybridisa-
tion in several per cent of cases of squamous cell carcinomas
but neither in small cell carcinoma nor in adenocarcnoma
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thus far (Stremlau et al., 1985; Ostrow et al., 1987; Syrjanen
et al., 1989; Bejui et al., 1990; Yousem et al., 1992). To
provide a more accurate evaluation of the association of
HPV with lung cancer, we examined the existence of HPV
DNA in lung cancer tissues by a polymerase chain reaction
(PCR) method and dot-blot hybridisation, and confirmed it
by analysing the PCR product with Southern blot hybridisa-
tion and the expression of E6-E7 mRNA with in situ hyb-
ridisation (ISH). Furthermore, the mechanisms involved in
pulmonary carcinogenesis associated with HPV are discussed.
Materialis a ndmthods
Tissue specimens and DNA preparation
Tissue from 36 lung cancers was obtained by surgical resec-
tion or autopsy from Hokkaido University Hospital, Sap-
poro Minami-Ichijo Hospital and National Sapporo Minami
Hospital during 1988 and 1992. Samples were taken 1-3 h
after death in autopsy cases. All samples were divided into
two parts, one frozen in liquid nitrogen and stored at - 80°C
for DNA preparation and the other routinely fixed in for-
malin and embedded in paraffin for haematoxylin and eosin
staining and ISH. According to the 1981 WHO classification,
they were diagnosed histopathologically as adenocarcinoma
(n = 22), squamous cell carcinoma (n = 10), small-cell car-
cinoma (n = 2), adenosquamous carcinoma (n = 1) and
metastatic lung cancer of tongue carcinoma (n = 1). Genomic
DNA was isolated by proteinase K digestion followed by
phenol/chloroform extraction and ethanol precipitation
(Maniatis et al., 1989).
Primers andprobesforpotjymerase chain reaction (PCR)
Type-specific primers and probes were synthesised on a DNA
synthesiser (MilfiGen/Bioresearch, Brulington, USA) on the
basis of published sequences of HPV-16, -18 and -33, as
previously described (Shimada et al., 1990). In brief, the
primer p16-1 (5'-AAGGGCGTAACCGAAATCGGT-3') was
located close to the 5' end of the E6 sense sequence of
HPV-16, which was available as a common primer of HPV-
16, -18 and -33. The primers p16-2R (5'-GTTTGCAGCTCT-
GTGCATA-3'), pl8-2R (5'-GTGTTCAGTTCCGTGCACA-
3') and p33-2R (5'-GTCTCCAATGCFTGGCACA-3'), cor-
responding to type-specific E6 antisense sequences of
HPV-16, -18 and -33 respectively, were located in the middleof E6 open reading frame (ORF). The oligonucleotide
probes pB16-I (5'-CAT`I-TATGCACCAAAAGAGAACT-
GCAATG-3), pB18-I (5'-TGAGAAACACACCACAATAC-
TATGGCGCGC-3') and pB33-I (5'-CATTlTGCAGTAAG-
GTACTGCACGACTATG-3) were also type-specific for
HPV-16, -18 and -33 respectively, and located in the middle
of amplified regions.
PCR anddot-blot hybridisation
PCR was performed essentially as described by Shimada et
al. (1990). Cloned HPV-16, -18 and -33 plasmid DNA were
used as positive control templates for PCR. Each cloned
HPV DNA or cellular DNA (500 ng) was denatured at 94C
for 10 min, and placed in the reaction mixture (50 p1) con-
taining 10 mM Tris-HCL pH 8.3, 50 mM potassium chloride,
1.5 mM magnesium chloride, 200 Lm each dNTP, 100 pg m1'
gelatin, 2.5 units of Taq polymerase and 0.2 #M of each
primer. The mixture was subjected to 35 cycles of
amplification using a DNA thermal cycler (Perkin-Elmer
Cetus, Norwalk, CT, USA). Each cycle included denatura-
tion at 94-C for 1min, annealing at 55C for 2min and
extension at 72-C for 2 min. To avoid false-positive results, a
reagent control (no template DNA) was included with each
amplification. A 1-p aliquot of the reaction mixture was
dotted onto a nylon membrane filter (Biodyne Nylon Mem-
branes, Pall BioSupport, East Hills, USA) and hybridised
with each 3P end-labelled HPV type-specific oligonucleotide
probe by dot-blot analysis. Filters were washed twice in
0.2 x SSC, 0.1% SDS, at 55C for 20 min. Finally, the filters
were autoradiographed using Kodak XAR-5 film (Kodak,
Rochester, NY, USA).
Southern blot hybridisation
The amplified products of the three HPV-I8-positive cases
and four HPV-18-negative cases in PCR and dot-blot
analyses were further confirmed by Southern blot analysis. A
1.5% agarose gel in which 20L1 of the PCR products was
separated by eectrophoresis was denatured in 0.2 N sodium
hydroxide, 0.6 M sodium chloride and neutralised in 1 M
Tris-HCI, pH 7.5, 0.6 M sodiumn chloride. The amplified pro-
ducts were transferred to a nylon membrane filter and cross-
linked using ultraviolet exposure. The filter was incubated in
prehybridisation solution consisting of 50% formamide,
5 x SSPE, 0.3% SDS, 10 x Denhardt's solution and 250 pg
ml-' herring testis DNA at 42-C overnight. HPV-18 DNA
probe was labelled with [a-cuPJdCTP (3000 Ci mmol-', Amer-
sham, Tokyo, Japan) by random priming and added to
prehybridisation solution. Hybridisation was carried out at
42-C for 16h. The filter was washed twice in 0.2 x SSC,
0.1% SDS, at 60-C for 20 min and then autoradiographed
using Kodak XAR-5 film.
In situ hybridisation (ISH)
ISH for the detection of the E6-E7 mRNA of HPV-18 using
a nboprobe was performed in HPV-18-positive cases essen-
tially as descsribed by Stoler et al. (1992). In brief, an HPV-
18 clone in pBR322 was subcloned into the transription
vector pGEM3 (Promega, Madison, WI, USA) as a sub-
genomic clone corresponding to the E6-E7 open reading
frames (ORFs) [BwnHI (120) to HincH (658)]. TIhe plasmid
was lnearised with BwnHI (Takara, Osaka, Japan) or HincHl
(Takara) and then an antisense or sense probe was syn-
thesised with SP6 or T7 RNA polymerase (Boehringer Man-
nheim, Ma Germany) respectively, in the presence of
digoxigenin-UTP (Boehringer Mannbeim) or [5SUTP
(>1000Cimmol[ , Amersham). Following the probe syn-
thesis, the template DNA was digested with RNAse-free
DNAse (Boehringer Mannheim), and the probe was sub-
jected to limited alkaline hydrolysis and reduced to an
average size of 200 nucleotides.
Five-micron-thick tissue sections mounted on APS-coated
slides (Matsunami Glass, Japan) were deparaffinised in
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xylene and rehydrated through a graded series of ethanol.
Sections were treated with 0.2 N hydrochloric acid at room
temperature for 10min, l0ILgml-' proteinase K at 37C for
10mi, refixed with 4% paraformaldehyde and then
acetylated with 0.25% (v/v) acetic anhydride. Slides were
dehydrated through a graded series of ethanol and air dried.
Hybridisation was carried out at 37C for 16h in humid
conditions (Tm- 20'C). The probe concentrations were
0.8 pg ml-' for a digoxigenin-labelled probe and I x I07
c.p.m. ml-' for a ES-labelled probe. After hybridisation, slides
were washed under high-stringency conditions (Tm- O1C).
For digoxigenin-labelled probe, immunodetection was carried
out by using a DIG ELISA Detection Kit (Boehringer Mann-
heim). In brief, sections were incubated with alkaline phos-
phatase conjugated antidigoxigenin antibody diluted 1:500 in
0.1M Tris-HCI, pH 7.5, 0.15M sodiurm chloride for 30min.
After washes, slides were immersed in a mixture of nitroblue
tetrazolium (NBT) and 5-bromo-4-chloro-3-indolyl phos-
phate (BCIP) solution overnight and counterstained with
methyl green. For a 3S-labelled probe, slides were overlaid
with Konika NRM-2 autoradiography emulsion (Konika,
Tokyo, Japan), exposed for 3 weeks at 4'C, developed photo-
graphically and counterstained with haematoxylin and eosin.
For controls, a known HPV-18 E6-E7 mRNA-positive
cell line (HeLa) and a known HPV-negative cell line (C-33A)
(Schwarz et al., 1985; Yee et al., 1985) were grown on
chamber sde gss (Nunc, Napervilk, USA), fixed with 4%
paraformaldehyde in phosphate-buffered saline (PBS) for
30mi, and then processed for ISH.
Res
We performed the PCR using HPV type-specific primers and
dot-blot hybridisation assay using HPV type-specific probes
to elucidate the role of HPV in the development and progres-
sion of lung cancer. HPV-18 DNA was detected in three
(8%) of 36 specimens; histologically, in one (10%) of 10
squamous cell carcinomas and two (9%) of 22 adenocar-
cinomas (Table I). The results of the PCR and dot-blot
hybridisation of HPV-18 in 19 cases are shown in Figure la.
Neither HPV-16 nor HPV-33 DNA was detected in any case
examined (Figure lb and data not shown).
The above result on HPV-18 by the PCR and dot-blot
analyses was confirmed by Southern blot analysis following
PCR. As shown in Figure 2, an expected 140bp band was
observed in the HPV-18-positive cases in the dot-blot
analysis. No positive signals were observed in HPV-18-
negative cases.
In the HPV-positive cases, we performed ISH using
digoxigenin-labeled riboprobes corresponding to the E6-E7
region of HPV-18 to confirm that the result of PCR was not
false positive and that the tumour cells in fact expressed
mRNA of the E6-E7 transforming region.
An HPV-positive cell line (HeLa) and an HPV-negative
cell line (C-33A) were used as controls. Strong cytoplasmic
signals with the E6-E7 aniisense probe and no signals with
the sense probe were observed in HeLa cells (Figure 3a and
data not shown). No hybridised signals with either probe
were detected in C-33A cells (Figure 3b and data not shown).
The case of squamous cell carcinoma that was HPV-18-
positive in PCR analysis (case 1 in Table H) exhibited abun-
Table I Detection of HPV DNA in lung ancers
No. of HPV DNA type
cases 16 18 33
Squamous cell carcinoma 10 0 1 0
Adenocarcinoma 22 0 2 0
Adenosquamous carcinoma I 0 0 0
Small cellcarinoma 2 0 0 0
Metastatic hmg cancer oftongue 1 0 0 0
carcinoma
Total 36 0 3 0HPV in hn mce
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Figwe 1 Detection of HPV DNA using the PCR and dot-blot
hybridisation methods described in the Materials and methods
section. In this set of dot blottings, 19 amplified DNA fragments
from frozen tissue samples were dotted on to three different
membranes, and each membrane was hybridised to a type-specific
probe for HPV-16. -18 or -33. a, Hybridisation with probe pB18-
I for HPV-18. Two samples are positive (case I and case 14).
Controls are dotted in row 3. Columns 1, 2 and 3 are positive
controls of cloned HPV-16, -18 and -33 plasmid DNAs respec-
tively. NC (column 4) is a negative control (no template DNA).
b, Hybridisation with probe pB16-I for HPV-16. No sample was
positive. For controls, see a. No HPV-33 DNA was detected
(data not shown).
1 2 3 4 5 6 7 8 9 10
(bp)
1353-
1078
872 -
603-
310._
271J281 _.
234-_
194-
118-
72-
Figwe 2 Southern blot analysis of the PCR produc
in the Materials and methods section. After gel elek
the products were Southern blot transferred and hyb
a 3-P-labelled HPV-18 DNA probe. Lanes 1-3, t]
positive cases in dot-blot analysis; lanes 4-7, HPV
cases in dot-blot analysis; lanes 8, 9 and 10, cloned I
and -33 plasmid DNAs, respectively, for controls. Tl
product was confirmed to show an expected 140 bp
HPV-18-positive cases. qpX 174 DNA HaeIII digest w
size marker.
dant cytoplasmic hybridised signals and a traa
signals with the E6-E7 antisense probe in cancei
in some areas of keratinisation, whereas stromal
no hybridised signals (Figure 4a). The abundant
signals were considered to represent a high I
E6-E7 gene expression while the trace nuclear s
represent untransported mRNA precursors or be
sequences removed from E6*-E7 mRNA. This
Fiwe 3 In situ hybridisation with a digoxigenin-labelled E6-E7
antisense probe in controls. a. HPV-18-positive HeLa cell. Strong
cytoplasmic hybridised signals can be observed (bar = 50 Lm). b.
HPV-negative C-33A cell. No hybridised signals can be observed
(bar= 100pAm).
confirmed by the control hybridisation experiment with the
sense probe, which abolished the hybridised signals (Figure
4b). One case of adenocarcinoma with HPV-18 DNA in PCR
analysis (case 2 in Table II) showed cytoplasmic hybridised
signals with the antisense probe (Figure 5a). These signals
- HPV-18 were also abolished with the sense probe (Figure 5b).
(140 bp) A definite signal was not observed by this ISH method in
the other case of adenocarcinoma (case 3 in Table II). How-
ever, since case 3 showed poor preservation of morphology.
the RNA in this specimen was thought to have degenerated
:ts described too much for the digoxigenin-labelled probe to detect the
ctrophoresis, HPV E6-E7 message. In this case, cytoplasmic hybridised
nridised with signals were weakly observed by ISH using a "S-labelled
he HPV-18- antisense probe corresponding to the same E6-E7 region to
'-18-negative detect lesser amounts of transcripts sensitively (data not
HPV-16, -18 shown). Finally, we believe that not only HPV-18 DNA but
be amplified also expression of the E6-E7 viral oncogene was detected in
as used as a case 3, even though the transcript level was decreased by
degeneration.
Characteristics of the HPV-positive cases were analysed
and are shown in Table II. Strikingly, all the patients were
male smokers. Pathologically, case 1 was moderately
e of nuclear differentiated squamous cell carcinoma without koilocytotic
r cells except feature. Case 2 was moderately differentiated acinar adeno-
cells showed carcinoma in which cytoplasmic mucin and mitosis were
cytoplasmic often observed. Case 3 was well-differentiated papillary
level of the adenocarcinoma. In the HPV-positive cases, adjacent bronchi
;ignals might were examined for dysplasia, metaplasia, papillamatous
from intron lesion and koilocytotic feature. However, none of these
finding was findings could be observed in each case.
a
b
A ..t. .'..
X.... -:.. "... i7. ..::.. -,% 1.1-In the present study. we detected HPV-18 DNA in one (10%)
of 10 squamous cell carcinomas and two (9%) of 22
adenocarcinomas by the PCR method. Detection of high-risk
HPV in adenocarcinoma of the lung has not been reported
thus far. Several investigators have identified HPV-16 and -18
DNA in 3-12% of squamous cell carcinomas and in one
HPV in cmcera
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anaplastic carcinoma of the lung by in situ DNA hybridisa-
tion and Southern blot hybridisation (Stremlau et al., 1985;
Ostrow et al., 1987; Syrainen et al., 1989; Bejui et al., 1990;
Yousem et al., 1992). Our detection rate of high-risk HPV in
squamous cell carcinomas was compatible with previous
studies.
Two recent studies used PCR-based assays to screen for
HPVs in lung cancers and found none (Shamanin et al.,
Table H Characteristics of HPV-18-positive lung cancers
Case I Case 2 Case 3
Age (years) 58 72 72
Sex Male Male Male
Pack-years of smokinga 27 45 45
Pathological stage IV (Operation) IV (Autopsy) I (Operation)
Histology Squamous cell Acinar Papillary
carcinoma adenocarcinoma adenocarcinoma
Degree of differentiation Moderate Moderate Well
Tumour
Koilocytosis - -
Dyskeratosis +
Adjacent bronchi
Dysplasia
Metaplasia
Koilocytosis - -
aPack-years of smoking were calculated as number of years of smoking x average
number of packs smoked per day.
a
b b
Figwe 4 In situ hybridisation with digoxigenin-labelled E6-E7
probes in a case of squamous cell carcinoma which was HPV-18
positive in the PCR analysis. a, Antisense probe. Abundant
cytoplasmic hybridised signals and a trace of nuclear signals can
be observed in cancer cells except in some areas of keratinisation.
Stroma cells had no hybridised signals (bar = 100 pm). b, Sense
probe. The signals hybridised with the antisense probe were
abolished in the adjacent section (bar= 100npm).
Figwe 5 In situ hybridisation with digoxigenin-labelled E6-E7
probes in a case of adenocarcinoma which was HPV-18 positive
in PCR analysis. a, Antisense probe. Cytoplasmic hybridised
signals can be observed in adenocarcinoma cells (bar = 100pm).
Anthracotic lung tissue (arrow) can also be observed in the lung
cancer tissue. b, Sense probe. The signals hybridised with the
antisense probe were abolished in the adjacent section
(bar= 100pm).
.4 A.xHWV i. - cf
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1994; Szab6 et al., 1994). However, both of the published
papers used so-called consensus primers of PCR to cover a
broad spectrum of HPVs, and the sensitivities of their assays
were one genome copy per cell and one genome copy per ten
cells respectively. We used type-specific primers and probes
for detecting high-risk HPVs, and this method can detect one
copy per I10 cells (Shimada et al., 1990). Furthermore,
Shamanin et al. (1994) used the primers in the LI region,
which is often deleted for integration in cancer cells, while we
used the primers in the E6 region, which is always conserved
for the integration (Takabe et al., 1987). Therefore, we could
minimise false-negative results compared with these two
studies.
Although ISH is less sensitive than PCR, it makes it
possible to examine viral expression in infected cells and the
relationship between pathological changes and the presence
of HPV. With this method, we have demonstrated expression
of E6-E7 mRNA in lung cancer. This ISH result revealed
not only the presence of the HPV genome but also the
expression of the viral oncogene, suggesting that they play a
causative role in the development and progression in these
tumours. Furthermore, the absence of E6-E7 mRNA in
some areas of keratinisation in squamous cell carcinoma
suggested the presence of cellular control mechanisms for
viral mRNA transcription that might be related to the state
of differentiation of the cell as previously reported (Higgins
et al., 1991).
It is noteworthy that we detected HPV-18 in two cases of
adenocarcinoma, because HPV has been thought to infect
squamous cell metaplasia but not native columnar epithe-
lium, and thus not to be involved in the genesis of adenocar-
cinoma of the lung (Bejui et al., 1990). However, in cervical
cancer, high-risk HPV is known to be involved in the car-
cinogenesis of three major histological cell types: squamous,
glandular and small-cell types (Stoler et al., 1992). Whereas
HPV-16 is the most prevalent virus infecting the uterine
cervix and is closely associated with squamous cell car-
cinomas, and sometimes with adenocarcinomas, HPV-18 is
most consistently associated with adenocarcinomas and
small-cell neuroendocrine carcinomas of the cervix and less
frequently with squamous cell carcinomas (Tase et al., 1988;
Stoler et al., 1991). Together with these findings, our findings
suggest that HPV-18 can be involved in the pathogenesis of
adenocarcinoma of the lung as well as that of the cervix.
Stoler et al. (1992) found that most HPV-16 DNAs existed
in a mixed episomal and integrated state, whereas all HPV-18
DNAs existed in an integrated state, regardless of the cell
type. Therefore, they suggested three possibilities with regard
to the virus-host relationship, none of which were mutually
exclusive: first, the virus infected a multipotent precursor cell;
second, the virus preferentially infected a cell already com-
mitted to a certain cell type; and, third, the virus exerted
some influence on cell differentiation. Their suggestions and
our present findings that all three HPV-positive patients were
smokers indicated that HPV might infect multipotent basal
cells in the bronchial epithelium at sites of microabrasion
caused by smoking, or at the border of the metaplastic
mucosa, equivalent to the transitional zone of the uterine
cervix. Through these possible mechanisms, high-risk HPVs,
especially HPV-18, are thought to be involved in the develop-
ment and progression of both squamous cell carcinoma and
adenocarcinoma of the lung.
We only detected HPV-18, although previous studies
reported that HPV-16 was more prevalent than HPV-18 in
lung cancer in Western countries (Stremlau et al., 1985;
Ostrow et al., 1987; Syrjinen et al., 1989). This difference
might be caused by geographic or racial factors, as was
shown in laryngeal cancer (Anwar et al., 1993).
In a recent study it was shown that bronchial papillomas
associated with HPV-16 and/or -18 are at high risk for the
development of squamous cell carcinoma (Popper et al.,
1992). However, we could not find a papillomatous lesion in
the neighbouring area of the HPV-positive squamous cell
carcinoma. We suggest that not all squamous cell carcinomas
associated with HPV-18 arise from the benign papillomatous
lesion, which is consistent with the observation reported by
Syrjinen et al., (1989) that only four of 12 HPV DNA-
positive bronchial squamous cell carcinomas showed lesions,
including papilloma, suggestive of HPV infection.
p53 and RB proteins have been reported to be inactivated
by the E6 and E7 proteins of high-risk HPVs in vitro
(Munger et al., 1989; Scheffner et al., 1990; Werness et al.,
1990). It also has been reported that high-risk HPVs
cooperate with an activated ras oncoprotein to transform
baby rat kidney cells (Storey et al., 1988), and that E7
protein of high-risk HPV overcomes the inhibition of c-mvc
expression by transforming growth factor , (Pietenpol et al.,
1990). We examined the three HPV-positive lung cancers for
the mutation of p53 by the PCR-based single-strand confor-
mation polymorphism (SSCP) analysis of exon 5 to exon 9
and found p53 mutation in all three cases (in preparation).
This finding suggests that the cellular target for HPV is not
p53 in these cases and that there may be other cellular targets
for HPV. The molecular mechanisms involved in the develop-
ment and progression of lung cancer by HPV remain to be
determined.
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